Headquartered in San Diego, CA Fiscal year ends December NASDAQ: JANX januxrx.com
Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies using three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its lead candidate, JANX007, is a PSMA-targeted TRACTr in Phase 1b development for metastatic castration-resistant prostate cancer (mCRPC), including monotherapy in taxane-naïve patients and a combination cohort with darolutamide. Additional PSMA programs include JANX014, a double-masked PSMA-TRACTr in Phase 1, and JANX013, a CD28 co-stimulatory TRACIr being evaluated in Phase 1 in combination with JANX007. Beyond oncology, JANX011 is a CD19-targeted ARM in a Phase 1 healthy-volunteer study for potential autoimmune disease treatment, designed for deep B-cell depletion with limited cytokine release by selectively engaging TRBV6-expressing T cells. The company has no product sales; revenue currently comes from collaboration arrangements, and operations are funded by a cash and investment portfolio of roughly $945.7 million. Updated
The real catalyst lands November 9, when Janux shows the first human data from its JANX011 ARM platform in autoimmune disease, and $945.7 million in cash and investments means it can fund the follow-through regardless. A smaller loss this quarter, with R&D spending down year over year, narrowed the operating loss.
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets…
Pre-Market Stock Futures: The futures are trading flat after a stellar day across Wall Street, with all major indices finishing deep in positive territory. Traders cited an improving outlook for the Iran…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies using three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM).
The Wall Street consensus 12-month price target for JANX is $32.47.
